As Sandoz returns marketing rights for digital therapeutics to Pear, what does it mean for co-promote arrangements? (MM&M):
“Sandoz, the generics division of Novartis, is altering commercial course, returning marketing duties for two prescription digital therapeutics (DTx) back to Pear Therapeutics. The move, which some had anticipated, comes 18 months after the two signed a co-promotion deal.
Since the Sandoz/Pear pact was widely seen as a litmus test of sorts for pharma’s role in helping distribute this nascent technology, the commercial break-up raises questions about the viability of such partnerships going forward. It also highlights the parties’ sometimes conflicting priorities: [Read more…] about Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse